STRATA Skin Sciences to Report Third Quarter 2020 Financial Results on November 10, 2020
November 03 2020 - 8:00AM
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the
“Company”), a medical technology company in Dermatology and Plastic
Surgery dedicated to developing, commercializing, and marketing
innovative products for the treatment of dermatologic conditions,
today announced that it plans to release its third quarter
financial results before the market opens on Tuesday, November 10,
2020. Management will hold a conference call to review the
financial results and provide a corporate update starting at at
8:30 am Eastern time / 5:30 a.m. Pacific Time on the same day. The
conference call will be concurrently webcast.
The link to the webcast will be available on
the STRATA Skin Sciences website
at www.strataskinsciences.com under the investor
relations section and will be archived for future reference. To
listen to the conference call, please dial (800) 786-6705
(US/Canada) or (212) 271-4651 (International) and use the
conference ID number 21971988.
About STRATA Skin Sciences,
Inc.STRATA Skin Sciences is a medical technology company
in Dermatology and Plastic Surgery dedicated to developing,
commercializing and marketing innovative products for the treatment
of dermatologic conditions. Its products include the XTRAC excimer
laser and VTRAC lamp systems utilized in the treatment of
psoriasis, vitiligo and various other skin conditions.
The Company’s proprietary XTRAC® excimer laser
delivers a highly targeted therapeutic beam of UVB light to treat
psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma
diseases which impact over 35 million patients in the United States
alone. The technology is covered by multiple patents, including
exclusive rights for patents for the delivery of treatment to
vitiligo patients.
STRATA’s unique business model leverages
targeted Direct to Consumer (DTC) advertising to generate awareness
and utilizes its in-house call center and insurance advocacy teams
to increase volume for the Company’s partner dermatology
clinics.
The XTRAC business has used this proven DTC
model to grow its domestic dermatology partner network to over 789
clinics, with a worldwide installed base of over 2,000 devices. The
Company is able to offer 90% of DTC patients an introduction to
physicians prescribing a reimbursable solution, using XTRAC, within
a 10-mile radius of their house. The Company is a leader in
dermatology in-clinic business generation for its partners.
Investor Relations Contact:Leigh Salvo(415)
937-5404ir@strataskin.com
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Sep 2023 to Sep 2024